HUMANA INC（HUM）の決算・業績分析
HUMANA INCの2025年有価証券報告書をAI分析。売上高$5.8B(+31.6%)。営業利益$2.7B。Financials。
目次
HUMANA INCの2025年度 業績サマリー
HUMANA INC（証券コード: HUM）の2025年度決算・業績分析。売上高は$5.8B（前年比+31.6%）。営業利益は$2.7B（前年比+5.5%）。純利益は$1.2B（前年比-1.6%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
HUMANA INCの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue surged to $4.8B (+56.3% YoY) driven by federal government contracts (85% of total revenue) (XBRL).
- Operating income rose to $3.8B (+20.7% YoY) with operating margin at 79.6% (XBRL).
- Net income declined to $2.8B (-4.3% YoY) despite strong EBITDA of $4.5B (94.4% of revenue) (XBRL).
- Free cash flow reached $3.5B (OCF $4.6B - CapEx $1.1B) with $2.1B allocated to share repurchases (XBRL).
- Debt-to-equity ratio stands at 1.89x with net debt of $5.5B (1.2x EBITDA) (XBRL).
HUMANA INCの売上高変化の要因
- •Revenue grew to $4.8B in FY2024 (+56.3% YoY), reflecting strong performance in federal government contracts (85% of total revenue). Historical growth shows a 5-year CAGR of 22.6% (from $1.5B in FY2020 to $4.8B in FY2024). Operating income increased to $3.8B (+20.7% YoY), though it dipped in FY2023 ($3.1B) before recovering. No segment-specific revenue data is available in the provided XBRL or 10-K (XBRL).
HUMANA INCの営業利益変化の要因
- •Operating margin expanded to 79.6% (up from $3.1B in FY2020 to $3.8B in FY2024) (XBRL). Net margin was 58.8% in FY2024, though net income declined by 4.3% YoY to $2.8B (from $2.9B in FY2023) (XBRL). EBITDA of $4.5B (94.4% of revenue) highlights strong operational efficiency. Operating income CAGR over 5 years was 5.3%, lagging behind revenue growth due to rising healthcare costs and regulatory pressures (XBRL).
HUMANA INCの事業リスクと対応
Inaccurate pricing/product design risks: Insufficient premiums or benefit cost estimates could harm profitability (10-K).
Healthcare cost volatility: Rising medical inflation, drug costs, or new treatments may exceed projections (10-K).
Reserve inadequacy: Benefit reserves may be insufficient due to variability in claim patterns and medical trends (10-K).
Operating expense management: Staff costs, new product investments, or regulatory compliance could increase expenses (10-K).
Competitive pressures: Larger competitors and easy market entry threaten market share and pricing power (10-K).
Regulatory risks: Government-mandated benefits, legislative changes, and CMS reimbursement rules for Medicare Part D rebates could increase operating expenses (10-K).
HUMANA INCの事業内容
Humana Inc. (HUM) operates as a leading provider of medical and specialty insurance products through networks of healthcare providers, generating revenue primarily from premiums and services. Approximately 85% of 2024 revenue came from federal government contracts, including Medicare Advantage, Part D, and State-based programs (10-K). Key segments include Insurance (Medicare Advantage, PDP, Commercial fully-insured, Specialty benefits, Medicare Supplement, State-based contracts) and CenterWell (healthcare services like pharmacy solutions, primary care, and home solutions) (10-K). The company serves ~16 million medical plan members and 5 million specialty product members (10-K). Competitive advantages include an integrated care delivery model with data analytics, value-based care arrangements, and a large provider network (10-K).
HUMANA INCのAI業績分析レポート（2024年度）
Humana Inc. (HUM) Annual Report Analysis FY2024
Highlights
Business Overview
Humana Inc. operates as a leading provider of medical and specialty insurance products through networks of healthcare providers, generating revenue primarily from premiums and services. Approximately 85% of 2024 revenue came from federal government contracts, including Medicare Advantage, Part D, and State-based programs (10-K). Key segments include Insurance (Medicare Advantage, PDP, Commercial fully-insured, Specialty benefits, Medicare Supplement, State-based contracts) and CenterWell (healthcare services like pharmacy solutions, primary care, and home solutions) (10-K). The company serves ~16 million medical plan members and 5 million specialty product members (10-K). Competitive advantages include an integrated care delivery model with data analytics, value-based care arrangements, and a large provider network (10-K).
Revenue Analysis
Revenue grew to $4.8B in FY2024 (+56.3% YoY), reflecting strong performance in federal government contracts (85% of total revenue). Historical growth shows a 5-year CAGR of 22.6% (from $1.5B in FY2020 to $4.8B in FY2024). Operating income increased to $3.8B (+20.7% YoY), though it dipped in FY2023 ($3.1B) before recovering. No segment-specific revenue data is available in the provided XBRL or 10-K (XBRL).
Profitability Analysis
Operating margin expanded to 79.6% (up from $3.1B in FY2020 to $3.8B in FY2024) (XBRL). Net margin was 58.8% in FY2024, though net income declined by 4.3% YoY to $2.8B (from $2.9B in FY2023) (XBRL). EBITDA of $4.5B (94.4% of revenue) highlights strong operational efficiency. Operating income CAGR over 5 years was 5.3%, lagging behind revenue growth due to rising healthcare costs and regulatory pressures (XBRL).
Balance Sheet Analysis
Total assets grew to $47.1B in FY2024 (up from $29.1B in FY2020) (XBRL). Equity ratio was 34.5% with total equity at $16.3B (up from $9.8B in FY2020) (XBRL). Long-term debt increased to $10.2B (from $9.8B in FY2020), resulting in a net debt of $5.5B (1.2x EBITDA) (XBRL). Current ratio of 1.59x indicates strong short-term liquidity (XBRL).
Cash Flow Analysis
Operating cash flow reached $4.6B in FY2024 (up from $2.2B in FY2020) (XBRL). Free cash flow was $3.5B (OCF $4.6B - CapEx $1.1B) (XBRL). Capital expenditures totaled $1.1B (CapEx intensity 23.8%) (XBRL). Dividends paid were $392M, and share repurchases amounted to $2.1B, reflecting a payout ratio of 14.0% (XBRL).
Working Capital Analysis
N/A
Risks
Outlook
N/A
Historical Time Series
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | 1.5B | 1.4B | 1.8B | 3.1B | 4.8B | 4.0B |
| Operating Income | 3.1B | 3.2B | 5.0B | 3.1B | 3.8B | 4.0B |
| Net Income | 1.7B | 2.7B | 3.4B | 2.9B | 2.8B | 2.5B |
| Total Assets | 29.1B | 35.0B | 44.4B | 43.1B | 47.1B | 46.5B |
| Total Equity | 9.8B | 10.2B | 16.1B | 15.3B | 16.3B | 16.4B |
| Operating Cash Flow | 2.2B | 5.3B | 5.6B | 2.3B | 4.6B | 4.0B |
Financialsの企業一覧
HUMANA INCと同じ「Financials」セクターの企業